- Conditions
- Allergic Rhinitis
- Interventions
- Grass MATA MPL 10200, Grass MATA MPL 18200, Placebo
- Biological
- Lead sponsor
- Allergy Therapeutics
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Neptune City, New Jersey • Newark, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Malaria, Falciparum
- Interventions
- FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone, Malaria challenge
- Biological · Other
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Herpes Simplex Infection
- Interventions
- HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine, Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 30 Years · Female only
- Enrollment
- 8,323 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2009
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
- Conditions
- Hookworm Infection, Hookworm Disease
- Interventions
- Na-APR-1 (M74)/Alhydrogel®, Gluco-Pyranosylphospho-Lipid A Aqueous Formulation
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Gastroenteritis
- Interventions
- NoV GI.1/GII.4 Bivalent VLP Vaccine, Saline
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- Silver Springs, Maryland • St Louis, Missouri • Rochester, New York
- Conditions
- HIV Infections
- Interventions
- Aluminum hydroxide, Lipid A, Monophosphoryl, Lipid A, Liposome-encapsulated monophosphoryl, Syntex adjuvant formulation, MF59, Threonyl Muramyl Dipeptide, rgp120/HIV-1 SF-2, MTP-PE/MF59
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 1996
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Rochester, New York • Seattle, Washington
- Conditions
- Leishmaniasis
- Interventions
- GLA-SE, LEISH-F3, MPL-SE, SE
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Influenza Prevention, Seasonal Influenza
- Interventions
- VRC-FLUMOS0116-00-VP, ALFQ
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Norovirus Prevention
- Interventions
- Norovirus Bivalent VLP Vaccine, Placebo (Saline)
- Biological · Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 454 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- San Diego, California • San Francisco, California • Coral Gables, Florida + 6 more
- Conditions
- Healthy Volunteers, Norovirus
- Interventions
- NoV Vaccine
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 528 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 6 more
- Conditions
- Norovirus
- Interventions
- Norovirus GI.1/GII.4 Bivalent VLP Vaccine, 0.9% sodium chloride (saline)
- Biological · Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 7 more
- Conditions
- Influenza Prevention, Pandemic Influenza Prevention
- Interventions
- VRC-FLUMOS0122-00-VP, ALFQ
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland